p.7 抽出テキスト

September 25, 2018 Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 e278

CLINICAL STATEMENTS AND GUIDELINES tions relevant to these important concepts. The importance of a shared decision-making process in which the patient, family, and clinicians discuss risks and benefits of diagnostic and treatment options and consider the patients’ personal preferences is emphasized (see Section 15).

In developing this guideline, the writing committee reviewed previously published guidelines and related statements. Table  4 contains a list of guidelines and statements deemed pertinent to this writing effort and is intended for use as a resource, obviating repetition of existing guideline recommendations. During final production review of the guidelines, several recommendations were refined to better reflect the data and current recommended medical practice. These refinements were reviewed and approved by the writing committee, the Task Force, and ACC, AHA, and HRS organizational leadership. These recommendations were:

•	 Section 7.1.1., recommendation 1 •	 Section 7.1.3., recommendation 2 •	 Section 7.2.1., recommendation 1 •	 Section 7.9.1.4., recommendation 2 •	 Section 10.8., recommendation 6 Readers should refer to these sections for the updated text.

Table 4.  Associated Guidelines and Statements

Title Organization Publication Year (Reference) Guidelines Syncope ACC/AHA/HRS 2017S1.4–10 Heart failure ACCF/AHA 2017S1.4–11 2016,S1.4–12 and 2013S1.4–13 Valvular heart disease AHA/ACC 2017S1.4–14 and 2014S1.4–15 Supraventricular tachycardia ACC/AHA/HRS 2015S1.4–16 Ventricular arrhythmias and the prevention of sudden cardiac death ESC 2015S1.4–17 Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care AHA 2015S1.4–18 Atrial fibrillation AHA/ACC/HRS 2014S1.4–19 Non–ST-elevation acute coronary syndromes AHA/ACC 2014S1.4–20 Assessment of cardiovascular risk ACC/AHA 2013S1.4–21 ST-elevation myocardial infarction ACCF/AHA 2013S1.4–22 Acute myocardial infarction in patients presenting with ST-segment elevation ESC 2012S1.4–23 Device-based therapies for cardiac rhythm abnormalities ACCF/AHA/HRS 2012S1.4–24 Coronary artery bypass graft surgery ACCF/AHA 2011S1.4–25 Hypertrophic cardiomyopathy ACCF/AHA 2011S1.4–6 Percutaneous coronary intervention ACCF/AHA/SCAI 2011S1.4–26 Secondary prevention and risk reduction therapy for patients with coronary and

other atherosclerotic vascular disease AHA/ACCF 2011S1.4–27 Scientific Statements Wearable cardioverter-defibrillator therapy for the prevention of sudden

cardiac death AHA 2016S1.4–9 Optimal implantable cardioverter defibrillator programming and testing HRS/EHRA/APHRS/SOLAECE 2016S1.4–8 Treatment of cardiac arrest: current status and future directions: strategies to

improve cardiac arrest survival IOM 2015S1.4–28 Eligibility and disqualification recommendations for competitive athletes with

cardiovascular abnormalities ACC/AHA 2015S1.4–29 Ventricular arrhythmias EHRA/HRS/APHRS 2014S1.4–30 Arrhythmias in adult congenital heart disease PACES/HRS 2014S1.4–31 Implantable cardioverter-defibrillator therapy in patients who are not included or

not well represented in clinical trials HRS/ACC/AHA 2014S1.4–32 Cardiac sarcoidosis HRS 2014S1.4–33 Inherited primary arrhythmia syndromes HRS/EHRA/APHRS 2013S1.4–34 ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; APHRS, Asia Pacific Heart Rhythm Society; EHRA, European Heart Rhythm Association; ESC, European Society of Cardiology; HRS, Heart Rhythm Society; PACES, Pediatric and Congenital Electrophysiology Society; SCAI, Society for Cardiovascular Angiography and Interventions; and, SOLAECE, Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia.

Downloaded from http://ahajournals.org by on October 7, 2026